Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.070 GeneticVariation disease BEFREE Mutational analyses of matched SBT/carcinoma pairs revealed concordant profiles in 33/36 (92%) cases, of which 19 (53%) were KRAS mutant, 4 (11%) were BRAF mutant, and 10 (28%) were wild type for both genes. 31343420 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.070 GeneticVariation disease BEFREE Mutational analyses of matched SBT/carcinoma pairs revealed concordant profiles in 33/36 (92%) cases, of which 19 (53%) were KRAS mutant, 4 (11%) were BRAF mutant, and 10 (28%) were wild type for both genes. 31343420 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.070 GeneticVariation disease BEFREE A serous borderline - low-grade serous carcinoma pathway analogous to neoplastic transformation pathways seen in other organ systems has been proposed, based on global gene expression profiling, shared mutations in KRAS or BRAF, and in most cases, the presence of serous borderline tumour in de novo low-grade serous carcinoma. 29289348 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.070 GeneticVariation disease BEFREE We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome. 29027536 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.070 GeneticVariation disease BEFREE We investigated KRAS and BRAF mutation frequencies in the two types of implants of serous borderline tumor/atypical proliferative serous tumor in correlation with clinical outcome. 29027536 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.070 GeneticVariation disease BEFREE Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. 28873354 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.070 GeneticVariation disease BEFREE Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. 28873354 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.070 GeneticVariation disease BEFREE In this study, we correlated the morphologic and immunohistochemical phenotypes of 71 APSTs and 18 LGSCs with the mutational status of KRAS and BRAF, the most common molecular genetic changes in these neoplasms. 25188864 2014
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.070 GeneticVariation disease BEFREE A subset of cells characterized by abundant eosinophilic cytoplasm (EC), discrete cell borders, and bland nuclei was identified in all (100%) 25 BRAF-mutated APSTs but in only 5 (10%) of 46 APSTs without BRAF mutations (P<0.0001). 25188864 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.070 GeneticVariation disease BEFREE KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. 24549645 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.070 GeneticVariation disease BEFREE We present a patient with ovarian atypical proliferative serous tumor and low-grade serous carcinoma, related to KRAS mutation. 23711666 2013
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.070 GeneticVariation disease BEFREE KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. 24549645 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.070 GeneticVariation disease BEFREE In those 2 cases we found the same mutations of KRAS in both the atypical proliferative serous (borderline) tumor and the high-grade serous carcinoma component of the tumor, indicating a clonal relationship. 17592266 2007
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.070 GeneticVariation disease BEFREE BRAF V599E mutation in histologic samples was found in 5 (24%) of 21 SBTs, 1 (33%) of 3 MPSCs, 1 (17%) of 6 endometrioid carcinomas, but not detected in 42 conventional serous carcinomas, 12 mucinous borderline tumors, 10 mucinous, and 10 clear-cell carcinomas. 17309670 2007
Entrez Id: 407008
Gene Symbol: MIR223
MIR223
0.010 Biomarker disease BEFREE miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. 29079174 2017
Entrez Id: 6602
Gene Symbol: SMARCD1
SMARCD1
0.010 Biomarker disease BEFREE miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma. 29079174 2017
Entrez Id: 4893
Gene Symbol: NRAS
NRAS
0.010 GeneticVariation disease BEFREE In this study, we analyzed NRAS exon 3 mutational status in 98 cases that were diagnosed with SBT/atypical proliferative serous tumor, noninvasive LGSC, or invasive LGSC. 28873354 2017
Entrez Id: 51009
Gene Symbol: DERL2
DERL2
0.010 GeneticVariation disease BEFREE We present a patient with ovarian atypical proliferative serous tumor and low-grade serous carcinoma, related to KRAS mutation. 23711666 2013
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.010 Biomarker disease BEFREE While somatic mutations in the KRAS or BRAF, and rarely ERBB2, genes have been well characterized in SBTs, other genetic alterations have not been described. 23774303 2013
Entrez Id: 4609
Gene Symbol: MYC
MYC
0.010 AlteredExpression disease BEFREE Significant over-expression of the c-myc gene at Stage III compared with other stages, and one remarkable case of over-expression in a serous tumour of low malignant potential suggest that c-myc expression is temporarily activated at some stage(s) during tumorigenesis of ovarian cancer, especially of serous tumours. 1544716 1992